Back to Search
Start Over
Immune responses to hepatitis B surface antigen following epidermal powder immunization.
- Source :
-
Immunology & Cell Biology . Feb2003, Vol. 81 Issue 1, p52-58. 7p. - Publication Year :
- 2003
-
Abstract
- Summary Langerhans cells in the epidermis of skin are potent antigen-presenting cells that trigger the immune system to respond to invading microorganisms. We have previously shown that epidermal powder immunization with a powdered inactivated influenza virus vaccine, by targeting the Langerhans cell-rich epidermis, was more efficacious than deeper tissue injection using a needle and syringe. We now report enhanced humoral and cellular immune responses to recombinant hepatitis B surface antigen following epidermal powder immunization. We observed that epidermal powder immunization with unadjuvanted hepatitis B surface antigen elicited an antibody titre equivalent to that induced by the alum-adjuvanted vaccine delivered by intramuscular injection, suggesting that epidermal powder immunization can overcome the need for adjuvantation. We demonstrated that synthetic CpG oligonucleotides (CpG DNA) could be coformulated with hepatitis B surface antigen and delivered by epidermal powder immunization to further augment the antibody response and modulate T helper cell activities. Epidermal powder immunization of hepatitis B surface antigen formulated with CpG DNA formulations resulted in 1.5-2.0 logs higher IgG antibody titres than alum-adjuvanted commercial vaccines administered by intramuscular injection. Formulation of hepatitis B surface antigen with CpG DNA elicited an augmented IgG2a antibody response and increased frequency of IFN-γ secreting cells. In addition, CpG DNA was found to activate epidermal Langerhans cells and stimulate the production of TNF-α and IL-12 cytokines by epidermal cells, explaining its strong adjuvant activity following epidermal powder immunization. These results show that epidermal powder immunization is a safe and effective method to deliver hepatitis B surface antigen and the addition of new adjuvants, such as CpG DNA, may further enhance the efficacy of this vaccine. [ABSTRACT FROM AUTHOR]
- Subjects :
- *IMMUNIZATION
*HEPATITIS B
*LANGERHANS cells
Subjects
Details
- Language :
- English
- ISSN :
- 08189641
- Volume :
- 81
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Immunology & Cell Biology
- Publication Type :
- Academic Journal
- Accession number :
- 8937316
- Full Text :
- https://doi.org/10.1046/j.1440-1711.2003.01134.x